Ribociclib in adiuvante nel tumore della mammella HR+/HER2-, lo studio NATALEE
[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] Valentina Guarneri (Director of the Oncology 2 Unit – Veneto Oncology Institute and Full Professor, University of Padua) discusses and comments on the results of the NATALEE trial on adjuvant ribociclib, among the most anticipated at ASCO 2023: HR+, HER2- breast cancer is in fact the most common subtype of the disease and constitutes almost 70% of all breast cancer cases in the United States and worldwide.
▶︎
Tumore al seno, quarta parte: il carcinoma HER2 positivo
▶︎
Impact of immunotherapy infusion timing on DDFS and OS
▶︎
Chemioterapia - Effetti Collaterali: Come Prevenirli e Combatterli
▶︎
EV-302 Trial, 3.5-year update for EV + P in la/mUC
▶︎
Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li
▶︎
Clinical Cases #119 - RCC metastatico: selezione dei pazienti, scelta e timing della terapia
▶︎
Chemo Port: Things You Want to Know… But Didn’t Ask
▶︎
She Wasn't Even Done Singing Yet When The GOLD Confetti Filled The Stage! 🤩
▶︎
mCRC, ad ASCO 2026 importanti evidenze dallo studio BREAKWATER
▶︎
Before you Start or Refuse Cancer Therapy- WATCH THIS!
▶︎
Radiotherapy that changes the pathways of metastatic disease
▶︎
KEM Knowledge: Less and less chemotherapy for many breast cancer patients (NEW!)
▶︎
How Long Chemo Side Effects Really Last?
▶︎
Immuno + chemo in mNSCLC: two real-world studies
▶︎
Typische Krebssymptome: An welchen Anzeichen erkennen Sie frühzeitig Krebs? Darauf bitte achten
▶︎
Oncology Wednesdays | News from ASCO Part I - Lung cancer and rare tumors
▶︎
Clinical Cases #136 - Multidisciplinary management of advanced renal cell carcinoma
▶︎
Sacituzumab govitecan, an Italian real-world study analyzes the LTR patient population
▶︎
Krebs-Killer - diese 10 Nährstoffe schützen wirklich!
▶︎